FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccines (Basel) / Immunotherapy of Equine Sarcoids-From Early Approaches to In...
Vaccines2023; 11(4); 769; doi: 10.3390/vaccines11040769

Immunotherapy of Equine Sarcoids-From Early Approaches to Innovative Vaccines.

Abstract: Horses and other equid species are frequently affected by bovine papillomavirus type 1 and/or 2 (BPV1, BPV2)-induced skin tumors termed sarcoids. Although sarcoids do not metastasize, they constitute a serious health problem due to their BPV1/2-mediated resistance to treatment and propensity to recrudesce in a more severe, multiple form following accidental or iatrogenic trauma. This review provides an overview on BPV1/2 infection and associated immune escape in the equid host and presents early and recent immunotherapeutic approaches in sarcoid management.
Get Full Text
Publication Date: 2023-03-30 PubMed ID: 37112681PubMed Central: PMC10145708DOI: 10.3390/vaccines11040769Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article discusses the problem of skin tumors in equine species instigated by bovine papillomavirus type 1 and 2 (BPV1/2), highlighting its resistance to treatments, and presents innovative immunotherapeutic approaches to manage these tumors.

Overview of BPV1/2 Infection

  • The research primarily provides an overview on the infection caused by Bovine papillomavirus type 1 and/or 2 (BPV1, BPV2), which is commonly found in horses and other equid species.
  • This particular virus induces skin tumors known as sarcoids, which although do not spread to other parts of the body or metastasize, are a significant health problem. This is due to the resistance these tumors have developed against treatments as a result of the BPV1/2 infection.
  • Furthermore, these sarcoids have a tendency to recur in a more severe, multiple form following accidental or induced trauma, making them difficult to manage.

BPV1/2 and Immune Escape in Equids

  • Another important aspect of this research focuses on the immune escape associated with a BPV1/2 infection in equid hosts. This essentially refers to the ability of the virus to evade the host’s immune system, therefore establishing an infection and pushing the skin cells to grow into tumors.
  • The immune escape of the virus amplifies the severity of the infection, as it prevents the body from effectively fighting off the virus and the resulting tumors.

Immunotherapeutic Approaches in Sarcoid Management

  • Given the seriousness of BPV1/2-induced sarcoids in equids, the research also presents various immunotherapeutic approaches to manage these types of tumors.
  • The document provides insights into both early and recent methodologies, thereby offering an up-to-date understanding of how treatments have evolved and where current research is focused.
  • It appears to discuss innovative vaccines as key to future management of sarcoids. These modern, immunotherapy-based treatment approaches aim to stimulate the immune system to effectively combat the BPV1/2 virus, ultimately managing the stubborn sarcoids that result from these infections.

Cite This Article

APA
Jindra C, Hainisch EK, Brandt S. (2023). Immunotherapy of Equine Sarcoids-From Early Approaches to Innovative Vaccines. Vaccines (Basel), 11(4), 769. https://doi.org/10.3390/vaccines11040769

Publication

Vaccines
ISSN: 2076-393X
NlmUniqueID: 101629355
Country: Switzerland
Language: English
Volume: 11
Issue: 4
PII: 769

Researcher Affiliations

Jindra, Christoph
  • Division of Molecular Oncology and Hematology, Karl Landsteiner University of Health Sciences, 3500 Krems an der Donau, Austria.
  • Research Group Oncology (RGO), Division of Equine Surgery, Department for Companion Animals and Horses, University of Veterinary Medicine, 1210 Vienna, Austria.
Hainisch, Edmund K
  • Research Group Oncology (RGO), Division of Equine Surgery, Department for Companion Animals and Horses, University of Veterinary Medicine, 1210 Vienna, Austria.
Brandt, Sabine
  • Research Group Oncology (RGO), Division of Equine Surgery, Department for Companion Animals and Horses, University of Veterinary Medicine, 1210 Vienna, Austria.

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 113 references
  1. Knottenbelt D.C.. A suggested clinical classification for the equine sarcoid.. Clin. Tech. Equine Pract. 2005;4:278–295.
    doi: 10.1053/j.ctep.2005.10.008google scholar: lookup
  2. Nasir L., Reid S.W.J.. Bovine papillomaviruses and equine sarcoids. Papillomavirus Research: From Natural History to Vaccines and Beyond Volume 1. Caister Academic Press; Norfolk, UK: 2006; pp. 389–397.
  3. Scott D.W., Miller W.H., Jr.. Sarcoid.. Equine Dermatol. 2003;1:719–731.
  4. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses.. Virology 2004 Jun 20;324(1):17-27.
    doi: 10.1016/j.virol.2004.03.033pubmed: 15183049google scholar: lookup
  5. Campo M.S.. Introduction. Papillomavirus Research: From Natural History to Vaccines and Beyond Caister Academic Press; Norfolk, UK: 2006; pp. 1–2.
  6. Campo M.S.. Bovine papillomavirus: Old system, new lessons?. Papillomavirus Research: From Natural History to Vaccines and Beyond Caister Academic Press; Norfolk, UK: 2006; pp. 373–387.
  7. Olthof NC, Hrs CU, Kolligs J, Henfling M, Ramaekers FC, Cornet I, van Lent-Albrechts JA, Stegmann AP, Silling S, Wieland U, Carey TE, Walline HM, Gollin SM, Hoffmann TK, de Winter J, Kremer B, Klussmann JP, Speel EJ. Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines.. Int J Cancer 2015 Mar 1;136(5):E207-18.
    doi: 10.1002/ijc.29112pmc: PMC5370555pubmed: 25082736google scholar: lookup
  8. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?. J Pathol 2007 Aug;212(4):356-67.
    doi: 10.1002/path.2192pubmed: 17573670google scholar: lookup
  9. Walline HM, Komarck CM, McHugh JB, Bellile EL, Brenner JC, Prince ME, McKean EL, Chepeha DB, Wolf GT, Worden FP, Bradford CR, Carey TE. Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma.. Mol Cancer Res 2016 Oct;14(10):941-952.
    doi: 10.1158/1541-7786.MCR-16-0105pmc: PMC5065754pubmed: 27422711google scholar: lookup
  10. OLSON C Jr, COOK RH. Cutaneous sarcoma-like lesions of the horse caused by the agent of bovine papilloma.. Proc Soc Exp Biol Med 1951 Jun;77(2):281-4.
    doi: 10.3181/00379727-77-18750pubmed: 14854020google scholar: lookup
  11. Chambers G, Ellsmore VA, O'Brien PM, Reid SWJ, Love S, Campo MS, Nasir L. Association of bovine papillomavirus with the equine sarcoid.. J Gen Virol 2003 May;84(Pt 5):1055-1062.
    doi: 10.1099/vir.0.18947-0pubmed: 12692268google scholar: lookup
  12. Lunardi M, de Alcântara BK, Otonel RA, Rodrigues WB, Alfieri AF, Alfieri AA. Bovine papillomavirus type 13 DNA in equine sarcoids.. J Clin Microbiol 2013 Jul;51(7):2167-71.
    doi: 10.1128/JCM.00371-13pmc: PMC3697707pubmed: 23637294google scholar: lookup
  13. Jindra C, Kamjunke AK, Jones S, Brandt S. Screening for bovine papillomavirus type 13 (BPV13) in a European population of sarcoid-bearing equids.. Equine Vet J 2021 Aug 30;54(4):662-9.
    doi: 10.1111/evj.13501pmc: PMC9292424pubmed: 34459020google scholar: lookup
  14. Amtmann E, Müller H, Sauer G. Equine connective tissue tumors contain unintegrated bovine papilloma virus DNA.. J Virol 1980 Sep;35(3):962-4.
    doi: 10.1128/jvi.35.3.962-964.1980pmc: PMC288890pubmed: 6252350google scholar: lookup
  15. Bogaert L, Martens A, Kast WM, Van Marck E, De Cock H. Bovine papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors.. Vet Microbiol 2010 Dec 15;146(3-4):269-75.
    doi: 10.1016/j.vetmic.2010.05.032pubmed: 21095508google scholar: lookup
  16. Brandt S, Haralambus R, Shafti-Keramat S, Steinborn R, Stanek C, Kirnbauer R. A subset of equine sarcoids harbours BPV-1 DNA in a complex with L1 major capsid protein.. Virology 2008 Jun 5;375(2):433-41.
    doi: 10.1016/j.virol.2008.02.014pubmed: 18395238google scholar: lookup
  17. Wilson AD, Armstrong ELR, Gofton RG, Mason J, De Toit N, Day MJ. Characterisation of early and late bovine papillomavirus protein expression in equine sarcoids.. Vet Microbiol 2013 Mar 23;162(2-4):369-380.
    doi: 10.1016/j.vetmic.2012.10.010pubmed: 23123175google scholar: lookup
  18. Bogaert L, Martens A, Van Poucke M, Ducatelle R, De Cock H, Dewulf J, De Baere C, Peelman L, Gasthuys F. High prevalence of bovine papillomaviral DNA in the normal skin of equine sarcoid-affected and healthy horses.. Vet Microbiol 2008 May 25;129(1-2):58-68.
    doi: 10.1016/j.vetmic.2007.11.008pubmed: 18093754google scholar: lookup
  19. Carr EA, Théon AP, Madewell BR, Griffey SM, Hitchcock ME. Bovine papillomavirus DNA in neoplastic and nonneoplastic tissues obtained from horses with and without sarcoids in the western United States.. Am J Vet Res 2001 May;62(5):741-4.
    doi: 10.2460/ajvr.2001.62.741pubmed: 11341396google scholar: lookup
  20. Martens A, De Moor A, Ducatelle R. PCR detection of bovine papilloma virus DNA in superficial swabs and scrapings from equine sarcoids.. Vet J 2001 May;161(3):280-6.
    doi: 10.1053/tvjl.2000.0524pubmed: 11352485google scholar: lookup
  21. Trenfield K, Spradbrow PB, Vanselow B. Sequences of papillomavirus DNA in equine sarcoids.. Equine Vet J 1985 Nov;17(6):449-52.
    doi: 10.1111/j.2042-3306.1985.tb02553.xpubmed: 3000762google scholar: lookup
  22. Knottenbelt D.C.. Sarcoid.. Pascoe’s Principles and Practice of Equine Dermatology Saunders Elsevier; London, UK: 2009; pp. 387–407.
  23. Knottenbelt DC. The Equine Sarcoid: Why Are There so Many Treatment Options?. Vet Clin North Am Equine Pract 2019 Aug;35(2):243-262.
    doi: 10.1016/j.cveq.2019.03.006pubmed: 31097356google scholar: lookup
  24. Tarwid J.N., Fretz P.B., Clark E.G.. Equine sarcoids: A study with emphasis on pathological diagnosis.. Compend. Contin. Educ. Pract. Vet. 1985;7:293–300.
  25. Chow L.T., Broker T.R.. Mechanisms and regulation of papillomavirus DNA replication. Papillomavirus Research: From Natural History to Vaccines and Beyond Caister Academic Press; Norfolk, UK: 2006; pp. 53–71.
  26. Hainisch EK, Jindra C, Reicher P, Miglinci L, Brodesser DM, Brandt S. Bovine Papillomavirus Type 1 or 2 Virion-Infected Primary Fibroblasts Constitute a Near-Natural Equine Sarcoid Model.. Viruses 2022 Nov 28;14(12).
    doi: 10.3390/v14122658pmc: PMC9781842pubmed: 36560661google scholar: lookup
  27. Yuan Z, Gault EA, Campo MS, Nasir L. Different contribution of bovine papillomavirus type 1 oncoproteins to the transformation of equine fibroblasts.. J Gen Virol 2011 Apr;92(Pt 4):773-83.
    doi: 10.1099/vir.0.028191-0pubmed: 21177927google scholar: lookup
  28. Yuan ZQ, Gault EA, Gobeil P, Nixon C, Campo MS, Nasir L. Establishment and characterization of equine fibroblast cell lines transformed in vivo and in vitro by BPV-1: model systems for equine sarcoids.. Virology 2008 Apr 10;373(2):352-61.
    doi: 10.1016/j.virol.2007.11.037pubmed: 18191170google scholar: lookup
  29. Borzacchiello G, Iovane G, Marcante ML, Poggiali F, Roperto F, Roperto S, Venuti A. Presence of bovine papillomavirus type 2 DNA and expression of the viral oncoprotein E5 in naturally occurring urinary bladder tumours in cows.. J Gen Virol 2003 Nov;84(Pt 11):2921-2926.
    doi: 10.1099/vir.0.19412-0pubmed: 14573796google scholar: lookup
  30. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16.. Nature 1996 Mar 7;380(6569):79-82.
    doi: 10.1038/380079a0pubmed: 8598912google scholar: lookup
  31. Petti L, DiMaio D. Specific interaction between the bovine papillomavirus E5 transforming protein and the beta receptor for platelet-derived growth factor in stably transformed and acutely transfected cells.. J Virol 1994 Jun;68(6):3582-92.
    doi: 10.1128/jvi.68.6.3582-3592.1994pmc: PMC236862pubmed: 8189497google scholar: lookup
  32. Suprynowicz F.A., Campo M.S., Schlegel R.. Biologic activities of papillomavirus E5 proteins. Papillomavirus Research: From Natural History to Vaccines and Beyond Volume 1. Caister Academic Press; Norfolk, UK: 2006; pp. 97–114.
  33. Tong X, Howley PM. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton.. Proc Natl Acad Sci U S A 1997 Apr 29;94(9):4412-7.
    doi: 10.1073/pnas.94.9.4412pmc: PMC20736pubmed: 9114003google scholar: lookup
  34. DeMasi J, Huh KW, Nakatani Y, Münger K, Howley PM. Bovine papillomavirus E7 transformation function correlates with cellular p600 protein binding.. Proc Natl Acad Sci U S A 2005 Aug 9;102(32):11486-91.
    doi: 10.1073/pnas.0505322102pmc: PMC1182553pubmed: 16081543google scholar: lookup
  35. Brandt S. Immune response to bovine papillomavirus type 1 in equine sarcoid.. Vet J 2016 Oct;216:107-8.
    doi: 10.1016/j.tvjl.2016.07.012pubmed: 27687935google scholar: lookup
  36. Hainisch EK, Abel-Reichwald H, Shafti-Keramat S, Pratscher B, Corteggio A, Borzacchiello G, Wetzig M, Jindra C, Tichy A, Kirnbauer R, Brandt S. Potential of a BPV1 L1 VLP vaccine to prevent BPV1- or BPV2-induced pseudo-sarcoid formation and safety and immunogenicity of EcPV2 L1 VLPs in horse.. J Gen Virol 2017 Feb;98(2):230-241.
    doi: 10.1099/jgv.0.000673pubmed: 28284277google scholar: lookup
  37. Hainisch EK, Brandt S, Shafti-Keramat S, Van den Hoven R, Kirnbauer R. Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses.. Equine Vet J 2012 Jan;44(1):107-11.
    doi: 10.1111/j.2042-3306.2011.00390.xpmc: PMC3939654pubmed: 21895749google scholar: lookup
  38. Hartl B, Hainisch EK, Shafti-Keramat S, Kirnbauer R, Corteggio A, Borzacchiello G, Tober R, Kainzbauer C, Pratscher B, Brandt S. Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation.. J Gen Virol 2011 Oct;92(Pt 10):2437-2445.
    doi: 10.1099/vir.0.033670-0pmc: PMC5034893pubmed: 21715602google scholar: lookup
  39. Ragland WL, Spencer GR. Attempts to relate bovine papilloma virus to the cause of equine sarcoid: immunity to bovine papilloma virus.. Am J Vet Res 1968 Jul;29(7):1363-6.
    pubmed: 4298397
  40. Ragland WL, Spencer GR. Attempts to relate bovine papilloma virus to the cause of equine sarcoid: equidae inoculated intradermally with bovine papilloma virus.. Am J Vet Res 1969 May;30(5):743-52.
    pubmed: 5813668
  41. Voss JL. Transmission of equine sarcoid.. Am J Vet Res 1969 Feb;30(2):183-91.
    pubmed: 5392976
  42. Stanley M. Host defence and persistent human papillomavirus infection.. Curr Opin Virol 2021 Dec;51:106-110.
    doi: 10.1016/j.coviro.2021.09.010pubmed: 34628358google scholar: lookup
  43. Yuan ZQ, Bennett L, Campo MS, Nasir L. Bovine papillomavirus type 1 E2 and E7 proteins down-regulate Toll Like Receptor 4 (TLR4) expression in equine fibroblasts.. Virus Res 2010 Apr;149(1):124-7.
    doi: 10.1016/j.virusres.2010.01.008pubmed: 20109504google scholar: lookup
  44. Yuan ZQ, Nicolson L, Marchetti B, Gault EA, Campo MS, Nasir L. Transcriptional changes induced by bovine papillomavirus type 1 in equine fibroblasts.. J Virol 2008 Jul;82(13):6481-91.
    doi: 10.1128/JVI.00429-08pmc: PMC2447052pubmed: 18434409google scholar: lookup
  45. Nasir L, Brandt S. Papillomavirus associated diseases of the horse.. Vet Microbiol 2013 Nov 29;167(1-2):159-67.
    doi: 10.1016/j.vetmic.2013.08.003pubmed: 24016387google scholar: lookup
  46. Marchetti B, Gault EA, Cortese MS, Yuan Z, Ellis SA, Nasir L, Campo MS. Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain.. J Gen Virol 2009 Dec;90(Pt 12):2865-2870.
    doi: 10.1099/vir.0.014746-0pubmed: 19675187google scholar: lookup
  47. Steinbach A, Riemer AB. Immune evasion mechanisms of human papillomavirus: An update.. Int J Cancer 2018 Jan 15;142(2):224-229.
    doi: 10.1002/ijc.31027pubmed: 28865151google scholar: lookup
  48. De Falco F, Cutarelli A, Catoi AF, Uberti BD, Cuccaro B, Roperto S. Bovine delta papillomavirus E5 oncoprotein negatively regulates the cGAS-STING signaling pathway in cattle in a spontaneous model of viral disease.. Front Immunol 2022;13:937736.
    doi: 10.3389/fimmu.2022.937736pmc: PMC9597257pubmed: 36311756google scholar: lookup
  49. De Falco F, Cutarelli A, Gentile I, Cerino P, Uleri V, Catoi AF, Roperto S. Bovine Delta Papillomavirus E5 Oncoprotein Interacts With TRIM25 and Hampers Antiviral Innate Immune Response Mediated by RIG-I-Like Receptors.. Front Immunol 2021;12:658762.
    doi: 10.3389/fimmu.2021.658762pmc: PMC8223750pubmed: 34177899google scholar: lookup
  50. Broström H. Equine sarcoids. A clinical and epidemiological study in relation to equine leucocyte antigens (ELA).. Acta Vet Scand 1995;36(2):223-36.
    doi: 10.1186/BF03547691pmc: PMC8095413pubmed: 7484549google scholar: lookup
  51. Broström H, Fahlbrink E, Dubath ML, Lazary S. Association between equine leucocyte antigens (ELA) and equine sarcoid tumors in the population of Swedish halfbreds and some of their families.. Vet Immunol Immunopathol 1988 Oct;19(3-4):215-23.
    doi: 10.1016/0165-2427(88)90109-2pubmed: 3252614google scholar: lookup
  52. Meredith D, Elser AH, Wolf B, Soma LR, Donawick WJ, Lazary S. Equine leukocyte antigens: relationships with sarcoid tumors and laminitis in two pure breeds.. Immunogenetics 1986;23(4):221-5.
    doi: 10.1007/BF00373016pubmed: 3699852google scholar: lookup
  53. Triulzi T, Tagliabue E, Balsari A, Casalini P. FOXP3 expression in tumor cells and implications for cancer progression.. J Cell Physiol 2013 Jan;228(1):30-5.
    doi: 10.1002/jcp.24125pubmed: 22674548google scholar: lookup
  54. Gajewski TF. The expanding universe of regulatory T cell subsets in cancer.. Immunity 2007 Aug;27(2):185-7.
    doi: 10.1016/j.immuni.2007.08.001pubmed: 17723212google scholar: lookup
  55. Wang Y, Ma Y, Fang Y, Wu S, Liu L, Fu D, Shen X. Regulatory T cell: a protection for tumour cells.. J Cell Mol Med 2012 Mar;16(3):425-36.
    doi: 10.1111/j.1582-4934.2011.01437.xpmc: PMC3822920pubmed: 21895966google scholar: lookup
  56. Wilson AD, Hicks C. Both tumour cells and infiltrating T-cells in equine sarcoids express FOXP3 associated with an immune-supressed cytokine microenvironment.. Vet Res 2016 May 9;47(1):55.
    doi: 10.1186/s13567-016-0339-8pmc: PMC4862206pubmed: 27160146google scholar: lookup
  57. Geisshüsler H, Marti E, Stoffel MH, Kühni K, Stojiljkovic A, von Tscharner C, Vidondo B, Gerber V, Koch C. Quantitative analysis of infiltrating immune cells and bovine papillomavirus type 1 E2-positive cells in equine sarcoids.. Vet J 2016 Oct;216:45-52.
    doi: 10.1016/j.tvjl.2016.06.016pubmed: 27687925google scholar: lookup
  58. Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, Kirkpatrick N, Gedye C, Moss D, Ng SP, MacGregor D, Davis ID, Cebon J, Chen W. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.. Cancer Res 2008 Apr 15;68(8):3001-9.
    doi: 10.1158/0008-5472.CAN-07-5664pubmed: 18413770google scholar: lookup
  59. Luo Q, Zhang S, Wei H, Pang X, Zhang H. Roles of Foxp3 in the occurrence and development of cervical cancer.. Int J Clin Exp Pathol 2015;8(8):8717-30.
    pmc: PMC4583848pubmed: 26464616
  60. Wang X, Lang M, Zhao T, Feng X, Zheng C, Huang C, Hao J, Dong J, Luo L, Li X, Lan C, Yu W, Yu M, Yang S, Ren H. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3(+)Treg cells in pancreatic ductal adenocarcinoma.. Oncogene 2017 May 25;36(21):3048-3058.
    doi: 10.1038/onc.2016.458pmc: PMC5454319pubmed: 27991933google scholar: lookup
  61. Ashrafi GH, Piuko K, Burden F, Yuan Z, Gault EA, Müller M, Trawford A, Reid SWJ, Nasir L, Campo MS. Vaccination of sarcoid-bearing donkeys with chimeric virus-like particles of bovine papillomavirus type 1.. J Gen Virol 2008 Jan;89(Pt 1):148-157.
    doi: 10.1099/vir.0.83267-0pubmed: 18089738google scholar: lookup
  62. Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunostimulatory cytokines in cancer therapy.. Oncoimmunology 2014;3:e29030.
    doi: 10.4161/onci.29030pmc: PMC4091551pubmed: 25083328google scholar: lookup
  63. Mattil-Fritz S, Scharner D, Piuko K, Thönes N, Gissmann L, Müller H, Müller M. Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric papillomavirus-like particles.. J Gen Virol 2008 Jan;89(Pt 1):138-147.
    doi: 10.1099/vir.0.83266-0pubmed: 18089737google scholar: lookup
  64. Jindra C, Hainisch EK, Rümmele A, Wolschek M, Muster T, Brandt S. Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.. PLoS One 2021;16(11):e0260155.
    doi: 10.1371/journal.pone.0260155pmc: PMC8604313pubmed: 34797850google scholar: lookup
  65. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity.. Cell 2006 Feb 24;124(4):783-801.
    doi: 10.1016/j.cell.2006.02.015pubmed: 16497588google scholar: lookup
  66. Newton K, Dixit VM. Signaling in innate immunity and inflammation.. Cold Spring Harb Perspect Biol 2012 Mar 1;4(3).
    doi: 10.1101/cshperspect.a006049pmc: PMC3282411pubmed: 22296764google scholar: lookup
  67. Dajon M, Iribarren K, Cremer I. Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword.. Immunobiology 2017 Jan;222(1):89-100.
    doi: 10.1016/j.imbio.2016.06.009pubmed: 27349597google scholar: lookup
  68. Calmette A. Preventive Vaccination Against Tuberculosis with BCG.. Proc R Soc Med 1931 Sep;24(11):1481-90.
    doi: 10.1177/003591573102401109pmc: PMC2182232pubmed: 19988326google scholar: lookup
  69. Cardillo F, Bonfim M, da Silva Vasconcelos Sousa P, Mengel J, Ribeiro Castello-Branco LR, Pinho RT. Bacillus Calmette-Guérin Immunotherapy for Cancer.. Vaccines (Basel) 2021 May 1;9(5).
    doi: 10.3390/vaccines9050439pmc: PMC8147207pubmed: 34062708google scholar: lookup
  70. Murphy JM, Severin GA, Lavach JD, Hepler DI, Lueker DC. Immunotherapy in ocular equine sarcoid.. J Am Vet Med Assoc 1979 Feb 1;174(3):269-72.
    pubmed: 447557
  71. Wyman M, Rings MD, Tarr MJ, Alden CL. Immunotherapy in equine sarcoid: a report of two cases.. J Am Vet Med Assoc 1977 Sep 1;171(5):779-51.
    pubmed: 332676
  72. Klein WR, Bras GE, Misdorp W, Steerenberg PA, de Jong WH, Tiesjema RH, Kersjes AW, Ruitenberg EJ. Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial.. Cancer Immunol Immunother 1986;21(2):133-40.
    doi: 10.1007/BF00199861pubmed: 3633215google scholar: lookup
  73. Knottenbelt DC, Kelly DF. The diagnosis and treatment of periorbital sarcoid in the horse: 445 cases from 1974 to 1999.. Vet Ophthalmol 2000;3(2-3):169-191.
    doi: 10.1046/j.1463-5224.2000.00119.xpubmed: 11397301google scholar: lookup
  74. Martens A, De Moor A, Vlaminck L, Pille F, Steenhaut M. Evaluation of excision, cryosurgery and local BCG vaccination for the treatment of equine sarcoids.. Vet Rec 2001 Dec 1;149(22):665-9.
    doi: 10.1136/vr.149.22.665pubmed: 11765322google scholar: lookup
  75. Komáromy AM, Andrew SE, Brooks DE, Detrisac CJ, Gelatt KN. Periocular sarcoid in a horse.. Vet Ophthalmol 2004 May-Jun;7(3):141-6.
    doi: 10.1111/j.1463-5224.2004.04027.xpubmed: 15091319google scholar: lookup
  76. Lavach JD, Severin GA, Lueker D. Immunotherapy of periocular sarcoids in horses.. Vet Clin North Am Large Anim Pract 1984 Nov;6(3):513-8.
    doi: 10.1016/S0196-9846(17)30007-1pubmed: 6393545google scholar: lookup
  77. Owen RA, Jagger DW. Clinical observations on the use of BCG cell wall fraction for treatment of periocular and other equine sarcoids.. Vet Rec 1987 Jun 6;120(23):548-52.
    doi: 10.1136/vr.120.23.548pubmed: 3303640google scholar: lookup
  78. Klein WR. [Immunotherapy of squamous cell carcinoma of the bovine eye and of equine sarcoid].. Tijdschr Diergeneeskd 1990 Dec 15;115(24):1149-55.
    pubmed: 2264025
  79. EMA. List of Nationally Authorised Medicinal Products—Active Substance: BCG Vaccine, PSUS_A/00000304/201803. European Medicines Agency Amsterdam, The Netherlands: 2018.
  80. Kollipara R, Ekhlassi E, Downing C, Guidry J, Lee M, Tyring SK. Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV.. J Clin Med 2015 Apr 24;4(5):832-46.
    doi: 10.3390/jcm4050832pmc: PMC4470201pubmed: 26239450google scholar: lookup
  81. Nogueira SA, Torres SM, Malone ED, Diaz SF, Jessen C, Gilbert S. Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study.. Vet Dermatol 2006 Aug;17(4):259-65.
    doi: 10.1111/j.1365-3164.2006.00526.xpubmed: 16827669google scholar: lookup
  82. Pettersson CM, Broström H, Humblot P, Bergvall KE. Topical treatment of equine sarcoids with imiquimod 5% cream or Sanguinaria canadensis and zinc chloride - an open prospective study.. Vet Dermatol 2020 Dec;31(6):471-e126.
    doi: 10.1111/vde.12900pubmed: 33016520google scholar: lookup
  83. Haspeslagh M, Vlaminck LE, Martens AM. Treatment of sarcoids in equids: 230 cases (2008-2013).. J Am Vet Med Assoc 2016 Aug 1;249(3):311-8.
    doi: 10.2460/javma.249.3.311pubmed: 27439349google scholar: lookup
  84. Barros MR Jr, de Oliveira THA, de Melo CML, Venuti A, de Freitas AC. Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers.. J Immunol Res 2018;2018:2912671.
    doi: 10.1155/2018/2912671pmc: PMC5954921pubmed: 29854832google scholar: lookup
  85. Jebreel A, Mistry D, Loke D, Dunn G, Hough V, Oliver K, Stafford N, Greenman J. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer.. J Laryngol Otol 2007 Mar;121(3):246-52.
    doi: 10.1017/S0022215106002428pubmed: 17040593google scholar: lookup
  86. Peghini BC, Abdalla DR, Barcelos AC, Teodoro Ld, Murta EF, Michelin MA. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia.. Hum Immunol 2012 Sep;73(9):920-6.
    doi: 10.1016/j.humimm.2012.06.003pubmed: 22749886google scholar: lookup
  87. Torres-Poveda K, Bahena-Román M, Madrid-González C, Burguete-García AI, Bermúdez-Morales VH, Peralta-Zaragoza O, Madrid-Marina V. Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia.. World J Clin Oncol 2014 Oct 10;5(4):753-63.
    doi: 10.5306/wjco.v5.i4.753pmc: PMC4129538pubmed: 25302175google scholar: lookup
  88. Smola-Hess S., Pfister H.. Immune evasion in genital papillomavirus infection and cervical cancer: Role of cytokines and chemokines. Papillomavirus Research—From Natural History to Vaccines and Beyond Caister Academic Press; Norfolk, UK: 2006; pp. 321–339.
  89. Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.. Oncoimmunology 2017;6(3):e1277306.
    doi: 10.1080/2162402X.2016.1277306pmc: PMC5384349pubmed: 28405498google scholar: lookup
  90. Paradkar PH, Joshi JV, Mertia PN, Agashe SV, Vaidya RA. Role of cytokines in genesis, progression and prognosis of cervical cancer.. Asian Pac J Cancer Prev 2014;15(9):3851-64.
    doi: 10.7314/APJCP.2014.15.9.3851pubmed: 24935564google scholar: lookup
  91. Wrangle JM, Patterson A, Johnson CB, Neitzke DJ, Mehrotra S, Denlinger CE, Paulos CM, Li Z, Cole DJ, Rubinstein MP. IL-2 and Beyond in Cancer Immunotherapy.. J Interferon Cytokine Res 2018 Feb;38(2):45-68.
    doi: 10.1089/jir.2017.0101pmc: PMC5815463pubmed: 29443657google scholar: lookup
  92. Den Otter W, Hill FW, Klein WR, Koten JW, Steerenberg PA, De Mulder PH, Rhode C, Stewart R, Faber JA, Ruitenberg EJ. Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up.. Cancer Immunol Immunother 1995 Jul;41(1):10-4.
    doi: 10.1007/s002620050193pubmed: 7641215google scholar: lookup
  93. Spoormakers TJ, Klein WR, Jacobs JJ, Van Den Ingh TS, Koten JW, Den Otter W. Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2.. Cancer Immunol Immunother 2003 Mar;52(3):179-84.
    doi: 10.1007/s00262-002-0369-0pubmed: 12649747google scholar: lookup
  94. Loschelder-Ostrowski J, Winter JC, Merle R, Klopfleisch R, Gehlen H. Treatment of equine sarcoids using recombinant poxviruses expressing feline interleukin-2.. Vet Dermatol 2021 Jun;32(3):283-e77.
    doi: 10.1111/vde.12941pubmed: 33728715google scholar: lookup
  95. Saba C, Eggleston R, Parks A, Peroni J, Sjoberg E, Rice S, Tyma J, Williams J, Grosenbaugh D, Leard AT. ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study.. J Vet Intern Med 2022 May;36(3):1179-1184.
    doi: 10.1111/jvim.16425pmc: PMC9151478pubmed: 35416353google scholar: lookup
  96. Kirnbauer R. Papillomavirus-like particles for serology and vaccine development.. Intervirology 1996;39(1-2):54-61.
    doi: 10.1159/000150475pubmed: 8957670google scholar: lookup
  97. Schiller J.T.. Papillomavirus Vaccines.. Papillomaviruses 2007;1:337–369.
  98. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.. Virology 1996 May 1;219(1):37-44.
    doi: 10.1006/viro.1996.0220pubmed: 8623552google scholar: lookup
  99. Espy B.M.K.. How to Treat Equine Sarcoids by Autologous Implantation.. AAEP Proc. 2008;54:68–73.
  100. Rothacker CC, Boyle AG, Levine DG. Autologous vaccination for the treatment of equine sarcoids: 18 cases (2009-2014).. Can Vet J 2015 Jul;56(7):709-14.
    pmc: PMC4466821pubmed: 26130832
  101. Figge G.. Multimodale, Kombinierte Tumortherapie und deren Behandlungserfolg bei hochgradigen Equinen Sarkoiden an der Pferdeklinik der Veterinärmedizinischen Universität Wien von 2001–2020. Master Thesis Veterinary University; Vienna, Austria: 2022.
  102. García-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P, Muster T. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems.. Virology 1998 Dec 20;252(2):324-30.
    doi: 10.1006/viro.1998.9508pubmed: 9878611google scholar: lookup
  103. Egorov A, Brandt S, Sereinig S, Romanova J, Ferko B, Katinger D, Grassauer A, Alexandrova G, Katinger H, Muster T. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells.. J Virol 1998 Aug;72(8):6437-41.
    doi: 10.1128/JVI.72.8.6437-6441.1998pmc: PMC109801pubmed: 9658085google scholar: lookup
  104. Romanova J, Krenn BM, Wolschek M, Ferko B, Romanovskaja-Romanko E, Morokutti A, Shurygina AP, Nakowitsch S, Ruthsatz T, Kiefmann B, König U, Bergmann M, Sachet M, Balasingam S, Mann A, Oxford J, Slais M, Kiselev O, Muster T, Egorov A. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.. PLoS One 2009 Jun 19;4(6):e5984.
    doi: 10.1371/journal.pone.0005984pmc: PMC2694350pubmed: 19543385google scholar: lookup
  105. Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, Kundi M, Popow-Kraupp T, Redlberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, Bergmann M, Romanova J, Roethl E, Morokutti A, Wolschek M, Ferko B, Seipelt J, Dick-Gudenus R, Muster T. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.. J Infect Dis 2010 Feb 1;201(3):354-62.
    doi: 10.1086/649428pubmed: 20039806google scholar: lookup
  106. Efferson CL, Tsuda N, Kawano K, Nistal-Villán E, Sellappan S, Yu D, Murray JL, García-Sastre A, Ioannides CG. Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells.. J Virol 2006 Jan;80(1):383-94.
    doi: 10.1128/JVI.80.1.383-394.2006pmc: PMC1317509pubmed: 16352563google scholar: lookup
  107. Ogbomo H, Michaelis M, Geiler J, van Rikxoort M, Muster T, Egorov A, Doerr HW, Cinatl J Jr. Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells.. Med Microbiol Immunol 2010 May;199(2):93-101.
    doi: 10.1007/s00430-009-0139-0pubmed: 20012989google scholar: lookup
  108. Ferko B, Kittel C, Romanova J, Sereinig S, Katinger H, Egorov A. Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.. J Virol 2006 Dec;80(23):11621-7.
    doi: 10.1128/JVI.01645-06pmc: PMC1642586pubmed: 16971432google scholar: lookup
  109. Kittel C, Ferko B, Kurz M, Voglauer R, Sereinig S, Romanova J, Stiegler G, Katinger H, Egorov A. Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.. J Virol 2005 Aug;79(16):10672-7.
    doi: 10.1128/JVI.79.16.10672-10677.2005pmc: PMC1182655pubmed: 16051859google scholar: lookup
  110. Sereinig S, Stukova M, Zabolotnyh N, Ferko B, Kittel C, Romanova J, Vinogradova T, Katinger H, Kiselev O, Egorov A. Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge.. Clin Vaccine Immunol 2006 Aug;13(8):898-904.
    doi: 10.1128/CVI.00056-06pmc: PMC1539114pubmed: 16893990google scholar: lookup
  111. van Rikxoort M, Michaelis M, Wolschek M, Muster T, Egorov A, Seipelt J, Doerr HW, Cinatl J Jr. Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame.. PLoS One 2012;7(5):e36506.
    doi: 10.1371/journal.pone.0036506pmc: PMC3341362pubmed: 22563505google scholar: lookup
  112. Wolschek M, Samm E, Seper H, Sturlan S, Kuznetsova I, Schwager C, Khassidov A, Kittel C, Muster T, Egorov A, Bergmann M. Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency.. J Virol 2011 Mar;85(5):2469-73.
    doi: 10.1128/JVI.01650-10pmc: PMC3067781pubmed: 21177819google scholar: lookup
  113. Jindra C, Huber B, Shafti-Keramat S, Wolschek M, Ferko B, Muster T, Brandt S, Kirnbauer R. Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.. PLoS One 2015;10(9):e0138722.
    doi: 10.1371/journal.pone.0138722pmc: PMC4575162pubmed: 26381401google scholar: lookup

Citations

This article has been cited 5 times.
  1. Monteiro MM, de Castro ELA, Pereira AJM, Thiesen R, Thiesen RMC, Salvarani FM. BCG Immunotherapy in Equine Sarcoid Treatment: Mechanisms, Clinical Efficacy, and Challenges in Veterinary Oncology. Viruses 2025 Sep 29;17(10).
    doi: 10.3390/v17101322pubmed: 41157593google scholar: lookup
  2. Smith CH, Stewart HL, Stefanovski D, Levine DG. Outcomes following autologous tumor tissue implantation with or without concurrent antineoplastic therapies in the treatment of sarcoids in 50 equids. Front Vet Sci 2025;12:1559519.
    doi: 10.3389/fvets.2025.1559519pubmed: 40417356google scholar: lookup
  3. Vychodilova L, Plasil M, Futas J, Kopecka A, Molinkova D, Wijacki T, Jahn P, Knoll A, Horin P. Genetic susceptibility to sarcoid in Arabian horses: associations with MHC class II and compound MHC class I/KLRA genotypes. Vet Res Commun 2025 May 1;49(3):184.
    doi: 10.1007/s11259-025-10748-2pubmed: 40310488google scholar: lookup
  4. Glikin GC, Finocchiaro LME. Clinical Trials of Cancer Immunogene Therapies in Companion Animals: An Update (2017-2024). Vet Sci 2025 Apr 3;12(4).
    doi: 10.3390/vetsci12040329pubmed: 40284831google scholar: lookup
  5. Labens R, Saba C, Williams J, Hollis A, Ensink J, Jose-Cunilleras E, Jordana-Garcia M, Bergvall K, Ruppin M, Condon F, Spelta C, Elce Y, De Ridder T, Morton J, McGee C, Reddell P. Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas. Equine Vet J 2026 Jan;58(1):89-104.
    doi: 10.1111/evj.14502pubmed: 40170619google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.